Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus News
3 min read

In This Article:

  • Cash and Investments: Approximately $863 million as of the end of Q2 2024.

  • Research and Development Expenses: $58.3 million for Q2 2024, up from $40.6 million in Q2 2023.

  • General and Administrative Expenses: $24.8 million for Q2 2024, compared to $13.3 million in Q2 2023.

  • Net Loss: $74.1 million for Q2 2024, compared to $51 million in Q2 2023.

  • Revenue: $0.4 million for Q2 2024, down from $1 million in Q2 2023.

  • Net Cash Used for Operating Activities: $45.6 million for Q2 2024.

  • Projected Cash Burn: Approximately $50 million to $60 million per quarter for the remainder of 2024.

Release Date: August 08, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) reported highly encouraging initial results from Phase 2 studies of Atumelnant in Congenital Adrenal Hyperplasia and Cushing's disease, which were well-received by the endocrinology community.

  • The company is on track to submit the NDA for paltusitine in acromegaly this year, with successful Phase 3 PATHFINDER studies supporting the submission.

  • Crinetics has a strong financial position with approximately $863 million in cash and investments, projected to fund operations into 2028.

  • The company has identified a Parathyroid Hormone receptor antagonist development candidate for hyperparathyroidism, with promising preclinical data.

  • Crinetics has a strategic relationship with Radionetics Oncology, potentially generating non-dilutive funding through a collaboration with Eli Lilly and Company.

Negative Points

  • Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) reported a net loss of $74.1 million for the second quarter of 2024, an increase from the $51 million loss in the same period in 2023.

  • Revenues for the quarter were only $0.4 million, a decrease from $1 million in the same period in 2023.

  • Research and development expenses increased significantly to $58.3 million, driven by higher personnel costs and manufacturing and development activities.

  • General and Administrative expenses rose to $24.8 million, reflecting increased personnel costs and outside services.

  • The company's Chief Financial Officer, Marc Wilson, announced his departure for personal reasons, which may impact financial leadership continuity.

Q & A Highlights

Q: What additional insights can we expect from the Phase 2 updates in CAH and Cushing's later this year, and where will these be presented? A: We will have final or top-line results in CAH and Cushing's disease, which will support the messages communicated at the Endocrine Society meeting. The updates will include a greater variety of patients and a detailed dose-response relationship, crucial for designing our Phase 3 program. Data from the 40 mg, 80 mg, and 120 mg cohorts will be available later this year. - Alan Krasner, Chief Medical Officer

Recommended Stories